Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
306,013

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.

Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised

by Zacks Equity Research

Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

by Zacks Equity Research

Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised

by Zacks Equity Research

Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

by Zacks Equity Research

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

by Zacks Equity Research

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

by Zacks Equity Research

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.